Strath contains 61 vital substances, from which each body takes what it needs,” says David Pestalozzi. Thirty-five studies of varying influence have been carried out to date. See Research at www.bio-strath.ch
Part 2 Strath (Bio-Stath) Tonic
To read Part 1 published 10 August – scroll this page. Part 3 will be published 13 August:
On today’s edition of Navigating the Cancer Maze, Grace Gawler interviews Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer immunotherapy treatment breakthroughs in many years. Visit germancancertreatments.com for more information.
On Navigating the Cancer Maze – Cancer Immunotherapy – Ground-breaking treatment in Cancer Medicine Grace Gawler -August 2, 2013
“Destroying cancer stem cells means fighting cancer at its roots”, says Horst Lindhofer, CEO of TRION Pharma. “Catumaxomab’s efficacy against this particularly aggressive and resistant population of cancer cells further supports its therapeutic potential for the treatment of EpCAM-positive carcinomas.”
On today’s edition of Navigating the Cancer Maze, I interview Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer treatment breakthroughs in many years. We know that The human immune system is usually quite effective at identifying and eliminating abnormal cells.
Cancer cells, however, can form tumors and spread throughout the body. Although chaotic in their behavior, cancer cells operate with high level intelligence to escape detection by our immune system’s control mechanisms. Often misunderstood, this is a fundamental principle in understanding how cancer cells behave and how immune recognition can be assisted. The new breakthrough cancer treatments capitalize on that information. It has been a long-standing vision of physicians and scientists to develop a treatment that can put the immune system back on track. TRION has achieved the goal with its trifunctional Triomab® antibodies. Listen to learn more or contact email@example.com for further details.
Listen to this interview at: http://www.voiceamerica.com/episode/72038/cancer-immunotherapy-ground-breaking-treatment-in-cancer-medicine
Catumaxomab (Removab®) is presently the only approved therapeutic antibody targeting EpCAM, a surface antigen that is widely expressed in the most frequent forms of human cancer. On April 20th this year, Removab® received EU approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Removab® is the first product world-wide to receive a regulatory approval for this indication. With its trifunctional mode of action, Removab® represents a new generation of antibodies using the body’s own immune system to help fight the tumor cells.
EpCAM: EpCAM or epithelial cell adhesion molecule is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas, such as breast, lung, colorectal, gastric, prostate and ovarian cancer. Catumaxomab (Removab®) is the only approved anti-EpCAM antibody available.
Triomab®: Trifunctional antibodies : Triomab® antibodies bind to cancer-specific surface antigens and recruit both T cells as well as accessory cells, such as macrophages, dendritic cells and natural killer cells, to the tumor site. As a result, they provide for a new quality of cancer cell killing, activating both arms of the immune system – the adaptive one with cytotoxic T cells as effectors and the innate one including accessory effector cells.
Triomab® antibodies are therefore very effective in destroying cancer cells and show a therapeutic effect at very low doses. Triomab® antibodies are a development of TRION Pharma GmbH Catumaxomab was invented by TRION Pharma and has been developed with Fresenius Biotech.